Narcolepsy

Patients with a rare disease, called narcolepsy, suffer of excessive daytime sleepiness and cataplexy (brief episodes of loss of muscle tone triggered by emotions). A study published in Nature reports, for the first time, the existence in patients with narcolepsy of autoreactive T lymphocytes (cells more

The European Medicines Agency's Committee on Human Medicinal Products (CHMP) at the request of the Agency’s Executive Director Guido Rasi has reviewed preliminary research results by the Finnish National Institute of Health and Welfare (THL) investigating differences in the immunological response tr more

Siegfried (USA) Inc announced that on April 1, 2010, a Supply Agreement with Jazz Pharmaceuticals Inc. was executed. Siegfried has the right to supply at least 60% of Jazz Pharmaceutical’s worldwide requirements of sodium oxybate, the active pharmaceutical ingredient in Xyrem® (sodium oxybate) oral more

Narcolepsy is a chronic neurological disorder that severely affects the day-to-day life and general well-being of the affected individuals. Unfortunately, treatments available to date are symptomatic therapies with an array of adverse effects. Animal studies showed that orexin peptide can be a mecha more

Aims and Objectives Based on class‐I studies, sodium oxybate is regarded as a first‐line treatment for both EDS and cataplexy. The cost‐effectiveness of sodium oxybate is largely unknown, though. In this study, we estimate the cost‐effectiveness of sodium oxybate as treatment for patients with n more

Hcrt gene inactivation in mice leads to behavioral state instability, abnormal transitions to paradoxical sleep, and cataplexy, hallmarks of narcolepsy. Sleep homeostasis is, however, considered unimpaired in patients and narcoleptic mice. We find that whereas Hcrtko/ko mice respond to 6-h sleep dep more